{"id":944,"date":"2024-08-06T15:27:09","date_gmt":"2024-08-06T07:27:09","guid":{"rendered":"https:\/\/flcube.com\/?p=944"},"modified":"2024-10-14T10:10:51","modified_gmt":"2024-10-14T02:10:51","slug":"eisais-q1-fy2024-revenues-reflect-mixed-results-with-leqembi-sales-doubling","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=944","title":{"rendered":"Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling"},"content":{"rendered":"\n

Eisai Co., Ltd (TYO: 4523<\/a>), a prominent Japanese pharmaceutical company, has released its financial results for the three-month first quarter of the fiscal year 2024, concluded on June 30, 2024. The company reported a slight decline of 4% in total revenues year-on-year (YOY), amounting to JPY 189 billion (USD 1.26 billion). Despite this, the actual pharmaceutical business revenues showed a positive trend, increasing by 3% YOY to JPY 186.6 billion (USD 1.25 billion).<\/p>\n\n\n\n

The financial report highlights a particularly strong performance for the Alzheimer’s disease therapy Leqembi (lecanemab), which saw its sales more than double, reaching JPY 6.3 billion (USD 42 million) YOY. Leqembi, first approved in the US in July 2023, has also gained approval in Japan and China, with the European approval still pending. Eisai is in a global development partnership with Biogen Inc. for Leqembi, leading its development and regulatory submissions, while both companies co-commercialize and co-promote the product.<\/p>\n\n\n\n

Eisai’s other significant revenue drivers include the cancer therapy Lenvima (lenvatinib), with sales reaching JPY 83.5 billion (USD 557.5 million), marking an 18% YOY increase, and the insomnia therapy Dayvigo (lemborexant), which showed a robust 29% YOY growth in sales to JPY 12.1 billion (USD 80.8 million). However, the report indicates that the company’s performance in its home market of Japan and in China lagged behind other competitive markets, as detailed in the accompanying financial tables.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[350,27,1151],"class_list":["post-944","post","type-post","status-publish","format-standard","hentry","category-company","tag-eisai","tag-finanical-reports","tag-tyo-4523"],"yoast_head":"\nEisai's Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results for the three-month first quarter of the fiscal year 2024, concluded on June 30, 2024. The company reported a slight decline of 4% in total revenues year-on-year (YOY), amounting to JPY 189 billion (USD 1.26 billion). Despite this, the actual pharmaceutical business revenues showed a positive trend, increasing by 3% YOY to JPY 186.6 billion (USD 1.25 billion).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=944\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai's Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=944\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-06T07:27:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-14T02:10:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=944#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=944\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling\",\"datePublished\":\"2024-08-06T07:27:09+00:00\",\"dateModified\":\"2024-10-14T02:10:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=944\"},\"wordCount\":227,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eisai\",\"Finanical Reports\",\"TYO: 4523\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=944#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=944\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=944\",\"name\":\"Eisai's Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-08-06T07:27:09+00:00\",\"dateModified\":\"2024-10-14T02:10:51+00:00\",\"description\":\"Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results for the three-month first quarter of the fiscal year 2024, concluded on June 30, 2024. The company reported a slight decline of 4% in total revenues year-on-year (YOY), amounting to JPY 189 billion (USD 1.26 billion). Despite this, the actual pharmaceutical business revenues showed a positive trend, increasing by 3% YOY to JPY 186.6 billion (USD 1.25 billion).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=944#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=944\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=944#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai's Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling - Insight, China's Pharmaceutical Industry","description":"Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results for the three-month first quarter of the fiscal year 2024, concluded on June 30, 2024. The company reported a slight decline of 4% in total revenues year-on-year (YOY), amounting to JPY 189 billion (USD 1.26 billion). Despite this, the actual pharmaceutical business revenues showed a positive trend, increasing by 3% YOY to JPY 186.6 billion (USD 1.25 billion).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=944","og_locale":"en_US","og_type":"article","og_title":"Eisai's Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=944","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-08-06T07:27:09+00:00","article_modified_time":"2024-10-14T02:10:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=944#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=944"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling","datePublished":"2024-08-06T07:27:09+00:00","dateModified":"2024-10-14T02:10:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=944"},"wordCount":227,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eisai","Finanical Reports","TYO: 4523"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=944#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=944","url":"https:\/\/flcube.com\/?p=944","name":"Eisai's Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-08-06T07:27:09+00:00","dateModified":"2024-10-14T02:10:51+00:00","description":"Eisai Co., Ltd (TYO: 4523), a prominent Japanese pharmaceutical company, has released its financial results for the three-month first quarter of the fiscal year 2024, concluded on June 30, 2024. The company reported a slight decline of 4% in total revenues year-on-year (YOY), amounting to JPY 189 billion (USD 1.26 billion). Despite this, the actual pharmaceutical business revenues showed a positive trend, increasing by 3% YOY to JPY 186.6 billion (USD 1.25 billion).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=944#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=944"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=944#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai’s Q1 FY2024 Revenues Reflect Mixed Results with Leqembi Sales Doubling"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/944","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=944"}],"version-history":[{"count":3,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/944\/revisions"}],"predecessor-version":[{"id":6334,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/944\/revisions\/6334"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}